BHVN — Biohaven Ltd.
—
NYSE ·
Health Care ·
Pharmaceuticals ·
CIK 1935979 ·
Last close
$11.28
Market Cap
$1.70B
52W High
$12.02
52W Low
$8.03
ADV30
2,634,917
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -130,428,000 | -130,532,000 | 466,406,000 | 273,074,000 | 336,906,000 |
| Dec 2025 | 0 | — | -142,734,000 | -145,555,000 | 451,447,000 | 229,957,000 | 399,375,000 |
| Sep 2025 | 0 | — | -169,382,000 | -173,443,000 | 409,123,000 | 184,847,000 | 426,283,000 |
| Jun 2025 | 0 | — | -211,701,000 | -198,147,000 | 550,415,000 | 165,797,000 | 415,828,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-594,232,000
Investing CF
$150,894,000
Financing CF
$617,764,000
CapEx
$-715,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-5.67
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-2,215,068,000
Inventory
—
Receivables
$2,597,000
ST Investments
$74,743,000
EBIT TTM
$-654,245,000
Pretax Income TTM
$-646,572,000
Interest Exp TTM
—
Analysts
17
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -745,378,000 | -738,822,000 | 451,447,000 | 399,375,000 | — | -609,438,000 |
| Dec 2024 | 0 | -885,111,000 | -846,422,000 | 615,107,000 | 191,671,000 | — | -582,453,000 |
| Dec 2023 | 0 | -436,051,000 | -408,168,000 | 513,212,000 | 85,237,000 | — | -331,725,000 |
| Dec 2022 | 0 | -567,932,000 | -570,279,000 | 661,783,000 | 123,012,000 | — | -297,689,000 |
TTM Snapshot
Revenues TTM
$443,853,000
NetIncome TTM
$-386,096,000
OpCashFlow TTM
$0
Assets (Latest)
$615,107,000
Forward EPS
$-1.95
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| MBX | MBX Biosciences, Inc. | $1.69B | $35.51 | — |
| NUVB | Nuvation Bio Inc. | $1.71B | $4.92 | — |
| INVA | Innoviva, Inc. | $1.68B | $22.74 | — |
| ZYME | Zymeworks Inc. | $1.67B | $22.88 | — |
| QURE | uniQure N.V. | $1.74B | $27.57 | — |
News headlines (Yahoo Finance, 1h cache)
Rapport ‘fully prepared’ to launch seizure drug solo, CEO says
2026-06-12 09:31 · Yahoo
Is Biohaven (BHVN) Quietly Reframing Its Investment Story Around Brain Energy and Precision Immunology?
2026-06-08 19:10 · Yahoo
Biohaven (BHVN) Valuation Check After New R&D Milestones In Immunology Neuroscience And Metabolic Programs
2026-06-07 21:17 · Yahoo
Is Biohaven (BHVN) the Best Stock That Have the Potential to Rise 1000%?
2026-06-05 21:03 · Yahoo
Why Is TG Therapeutics (TGTX) Down 5.7% Since Last Earnings Report?
2026-06-05 15:30 · Yahoo
Myriad (MYGN) Up 7.1% Since Last Earnings Report: Can It Continue?
2026-06-04 15:30 · Yahoo
Biohaven Reports First-in-Human Dosing of Oral PKM2 Modulator, BHV-8100, Targeting Metabolic Restoration and Immunomodulation
2026-06-01 11:30 · Yahoo
Biohaven Reports New Clinical Data in Epilepsy with Opakalim, a Selective Kv7.2/7.3 Activator, Highlighting Seizure Control and Markedly Differentiated Tolerability Profile
2026-05-26 11:30 · Yahoo
Biohaven (BHVN) Is Up 9.1% After Narrower Q1 Loss And New Mixed Shelf Registration - What's Changed
2026-05-06 23:15 · Yahoo
Biohaven Ltd. (BHVN) Upgraded to Buy: Here's Why
2026-05-05 16:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.